An Atlas of Variant Effects to understand the genome at nucleotide resolution

Douglas M. Fowler, David J. Adams, Anna L. Gloyn, William C. Hahn, Debora S. Marks, Lara A. Muffley, James T. Neal, Frederick P. Roth, Alan F. Rubin, Lea M. Starita, Matthew E. HurlesGenome 2023 · DOI · OpenAlex

Abstract

Sequencing has revealed hundreds of millions of human genetic variants, and continued efforts will only add to this variant avalanche. Insufficient information exists to interpret the effects of most variants, limiting opportunities for precision medicine and comprehension of genome function. A solution lies in experimental assessment of the functional effect of variants, which can reveal their biological and clinical impact. However, variant effect assays have generally been undertaken reactively for individual variants only after and, in most cases long after, their first observation. Now, multiplexed assays of variant effect can characterise massive numbers of variants simultaneously, yielding variant effect maps that reveal the function of every possible single nucleotide change in a gene or regulatory element. Generating maps for every protein encoding gene and regulatory element in the human genome would create an 'Atlas' of variant effect maps and transform our understanding of genetics and usher in a new era of nucleotide-resolution functional knowledge of the genome. An Atlas would reveal the fundamental biology of the human genome, inform human evolution, empower the development and use of therapeutics and maximize the utility of genomics for diagnosing and treating disease. The Atlas of Variant Effects Alliance is an international collaborative group comprising hundreds of researchers, technologists and clinicians dedicated to realising an Atlas of Variant Effects to help deliver on the promise of genomics.

Introduction: The Variant Interpretation Gap

We are currently in the midst of a "variant avalanche." While the cost of sequencing a human genome has dropped below that of a premium smartphone, our ability to interpret the resulting data has not kept pace. We have identified hundreds of millions of genetic variants, yet we lack functional understanding for over 99% of them.

Traditionally, the scientific community has been reactive. When a patient presents with a rare disease and a novel mutation is identified, researchers often spend months or years performing functional tests on that specific variant. This "one-by-one" approach is insufficient for the scale of human variation, leading to a proliferation of "Variants of Uncertain Significance" (VUS) in clinical reports. These VUS represent a primary bottleneck for precision medicine, as clinicians often cannot take action without definitive functional data.

Methodology: Multiplexed Assays of Variant Effect (MAVEs)

To bridge this gap, the Atlas of Variant Effects (AVE) Alliance champions a shift toward proactive functional genomics. The core technology enabling this shift is the Multiplexed Assay of Variant Effect (MAVE).

MAVEs allow researchers to characterize thousands of variants simultaneously through a three-step process:

  1. Library Creation: Synthesizing DNA libraries that contain every possible single-nucleotide change for a specific gene or regulatory element.
  2. Functional Selection: Introducing this library into a cellular environment and applying a selection pressure—such as cell growth, protein binding, or fluorescent reporters—to distinguish functional variants from those that impair activity.
  3. High-Throughput Readout: Using DNA sequencing to quantify the abundance of each variant before and after selection, resulting in a comprehensive variant effect map (often visualized as a heatmap).
The MAVE workflow (A) and the exponential growth of functional variant data over time (B).

Two primary modalities of MAVEs include Deep Mutational Scanning (DMS), which focuses on protein-coding sequences, and Massively Parallel Reporter Assays (MPRA), which target regulatory elements.

Current Progress and Data Infrastructure

The field has seen exponential growth in data generation. As of 2022, variant effect maps have been generated for hundreds of functional elements, encompassing over 11 million total variants. To manage this influx of data, the community utilizes MaveDB, an open-source repository designed to store and disseminate these massive functional datasets.

Despite this progress, current maps cover less than 1% of the known clinically relevant human genome. The AVE Alliance aims to coordinate global efforts to scale these assays, moving MAVE technology from specialized centers into labs worldwide through standardized protocols.

Strategic Impact and Clinical Utility

The ultimate goal of the Atlas is to provide a look-up table for every possible mutation before it is ever encountered in a patient. This proactive approach has already demonstrated clinical utility in high-profile genes such as BRCA1 (breast cancer), TP53 (tumor suppression), and PTEN.

The Atlas of Variant Effects serves as a foundational resource for diverse fields including drug development, precision medicine, and protein science.

Beyond direct clinical diagnostics, the Atlas provides "ground truth" data for artificial intelligence and machine learning models. Much as the Protein Data Bank enabled the success of AlphaFold, the AVE will provide the training data necessary for next-generation models to predict variant effects across the entire genome with high accuracy.

Challenges and Future Directions

Realizing a complete Atlas of Variant Effects remains a monumental task. Key challenges include:

  • Biological Context: A variant's effect may vary depending on the cell type, tissue environment, or developmental stage. Capturing this context-dependent biology requires more sophisticated assay systems.
  • The Non-Coding Genome: Mapping the 98% of the genome that regulates gene expression is significantly more complex than mapping protein-coding regions.
  • Scaling and Integration: Reducing the cost per variant and ensuring that functional maps are seamlessly integrated into clinical diagnostic workflows are essential for the Atlas to reach its full potential.

Conclusion

The Atlas of Variant Effects Alliance represents a global, collaborative effort to transform our understanding of the human genome. By moving from reactive testing to proactive mapping at nucleotide resolution, the Alliance aims to unlock the full promise of genomics for human health and fundamental biology.

Summary updated

Abstract

Sequencing has revealed hundreds of millions of human genetic variants, and continued efforts will only add to this variant avalanche. Insufficient information exists to interpret the effects of most variants, limiting opportunities for precision medicine and comprehension of genome function. A solution lies in experimental assessment of the functional effect of variants, which can reveal their biological and clinical impact. However, variant effect assays have generally been undertaken reactively for individual variants only after and, in most cases long after, their first observation. Now, multiplexed assays of variant effect can characterise massive numbers of variants simultaneously, yielding variant effect maps that reveal the function of every possible single nucleotide change in a gene or regulatory element. Generating maps for every protein encoding gene and regulatory element in the human genome would create an 'Atlas' of variant effect maps and transform our understanding of genetics and usher in a new era of nucleotide-resolution functional knowledge of the genome. An Atlas would reveal the fundamental biology of the human genome, inform human evolution, empower the development and use of therapeutics and maximize the utility of genomics for diagnosing and treating disease. The Atlas of Variant Effects Alliance is an international collaborative group comprising hundreds of researchers, technologists and clinicians dedicated to realising an Atlas of Variant Effects to help deliver on the promise of genomics.
BibTeX
@inproceedings{fowler2023atlas,
  author = {Douglas M. Fowler and David J. Adams and Anna L. Gloyn and William C. Hahn and Debora S. Marks and Lara A. Muffley and James T. Neal and Frederick P. Roth and Alan F. Rubin and Lea M. Starita and Matthew E. Hurles},
  title = {{An Atlas of Variant Effects to understand the genome at nucleotide resolution}},
  booktitle = {Genome},
  year = {2023},
  doi = {10.1186/s13059-023-02986-x},
}
Figure